×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EDIT – editas medicine, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EDIT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/27
07:55 am
edit
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference [Yahoo! Finance]
Low
Report
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference [Yahoo! Finance]
3/27
07:00 am
edit
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Low
Report
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
3/17
06:00 pm
edit
Is Editas Medicine Going to $0? [Yahoo! Finance]
Medium
Report
Is Editas Medicine Going to $0? [Yahoo! Finance]
3/15
01:48 pm
edit
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401 [Yahoo! Finance]
Low
Report
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401 [Yahoo! Finance]
3/12
10:52 am
edit
Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/10
01:01 pm
edit
Editas Medicine (EDIT) was upgraded by JonesTrading from "hold" to "buy". They now have a $8.00 price target on the stock.
Low
Report
Editas Medicine (EDIT) was upgraded by JonesTrading from "hold" to "buy". They now have a $8.00 price target on the stock.
3/9
09:04 pm
edit
Editas Medicine (EDIT) was given a new $6.00 price target by Robert W. Baird.
High
Report
Editas Medicine (EDIT) was given a new $6.00 price target by Robert W. Baird.
3/9
02:46 pm
edit
Editas Medicine (EDIT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $3.50 price target on the stock.
Low
Report
Editas Medicine (EDIT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $3.50 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
3/27
07:02 am
edit
Form 8-K Editas Medicine, Inc. For: Mar 26
Low
Report
Form 8-K Editas Medicine, Inc. For: Mar 26
3/26
06:05 pm
edit
Form SCHEDULE 13G/A Editas Medicine, Inc. Filed by: VANGUARD GROUP INC
Medium
Report
Form SCHEDULE 13G/A Editas Medicine, Inc. Filed by: VANGUARD GROUP INC
3/16
04:38 pm
edit
Form 4 Editas Medicine, Inc. For: Mar 12 Filed by: O'Neill Gilmore Neil
Medium
Report
Form 4 Editas Medicine, Inc. For: Mar 12 Filed by: O'Neill Gilmore Neil
3/16
04:36 pm
edit
Form 4 Editas Medicine, Inc. For: Mar 12 Filed by: Parison Amy
Medium
Report
Form 4 Editas Medicine, Inc. For: Mar 12 Filed by: Parison Amy
3/16
04:35 pm
edit
Form 4 Editas Medicine, Inc. For: Mar 12 Filed by: Burkly Linda
Medium
Report
Form 4 Editas Medicine, Inc. For: Mar 12 Filed by: Burkly Linda
3/9
04:51 pm
edit
Form 10-K Editas Medicine, Inc. For: Dec 31
High
Report
Form 10-K Editas Medicine, Inc. For: Dec 31
3/9
07:03 am
edit
Form 8-K Editas Medicine, Inc. For: Mar 09
High
Report
Form 8-K Editas Medicine, Inc. For: Mar 09
3/4
04:56 pm
edit
Form 4 Editas Medicine, Inc. For: Mar 03 Filed by: O'Neill Gilmore Neil
High
Report
Form 4 Editas Medicine, Inc. For: Mar 03 Filed by: O'Neill Gilmore Neil
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/7
Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
7.2%
11/12 Q3/2019 9/30/2019 EPS -0.660 ZacksConsensus -0.730 ActVsEst 0.070 - Beat 6.9%
3/5 Editas Medicine Inc (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock. 5.2%
3/4 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 5.1%
8/29 Editas Medicine to Participate in Upcoming Investor Conferences 4.5%
6/14 Form 4 Editas Medicine, Inc. For: Jun 12 Filed by: Hirsch Andrew 4.0%
10/19 Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth [Yahoo! Finance News] 3.7%
11/13 Editas Expands Its Celgene Partnership After Another Strong Quarter [The Motley Fool] 3.7%
11/28 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 3.6%
5/4 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.4%
11/12 Q3/2019 9/30/2019 EPS -0.660 ZacksConsensus -0.730 ActVsEst 0.070 - Beat 6.9%
3/5 Editas Medicine Inc (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock. 5.2%
3/4 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 5.1%
8/29 Editas Medicine to Participate in Upcoming Investor Conferences 4.5%
6/14 Form 4 Editas Medicine, Inc. For: Jun 12 Filed by: Hirsch Andrew 4.0%
10/19 Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth [Yahoo! Finance News] 3.7%
11/13 Editas Expands Its Celgene Partnership After Another Strong Quarter [The Motley Fool] 3.7%
11/28 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 3.6%
5/4 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.4%
TOP News Decliners
5/10
Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-10.9%
4/1 Better Buy: Editas Medicine vs Sangamo Therapeutics [The Motley Fool] -8.1%
2/26 Form S-8 Editas Medicine, Inc. -6.8%
2/21 Editas Medicine Inc (NASDAQ: EDIT) is now covered by analysts at Wells Fargo & Co. They set an "equal weight" rating and a $28.00 price target on the stock. -6.7%
2/22 Better Buy: Editas Medicine vs. Intellia [The Motley Fool] -6.2%
7/30 Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update -5.8%
8/27 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.1%
4/30 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update -4.9%
11/26 Better Buy: Editas Medicine or Sangamo Therapeutics? [The Motley Fool] -4.6%
3/20 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.6%
4/1 Better Buy: Editas Medicine vs Sangamo Therapeutics [The Motley Fool] -8.1%
2/26 Form S-8 Editas Medicine, Inc. -6.8%
2/21 Editas Medicine Inc (NASDAQ: EDIT) is now covered by analysts at Wells Fargo & Co. They set an "equal weight" rating and a $28.00 price target on the stock. -6.7%
2/22 Better Buy: Editas Medicine vs. Intellia [The Motley Fool] -6.2%
7/30 Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update -5.8%
8/27 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.1%
4/30 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update -4.9%
11/26 Better Buy: Editas Medicine or Sangamo Therapeutics? [The Motley Fool] -4.6%
3/20 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: